WO2003087306A8 - Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer - Google Patents

Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Info

Publication number
WO2003087306A8
WO2003087306A8 PCT/US2003/010462 US0310462W WO03087306A8 WO 2003087306 A8 WO2003087306 A8 WO 2003087306A8 US 0310462 W US0310462 W US 0310462W WO 03087306 A8 WO03087306 A8 WO 03087306A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
useful
detection
treatment
nucleic acid
Prior art date
Application number
PCT/US2003/010462
Other languages
French (fr)
Other versions
WO2003087306A2 (en
Inventor
Pia M Challita-Eid
Arthur B Raitano
Mary Faris
Wangmao Ge
Aya Jakobovits
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/165,044 external-priority patent/US20030149531A1/en
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to BRPI0308953-3A priority Critical patent/BR0308953A/en
Priority to AU2003223469A priority patent/AU2003223469A1/en
Priority to EP03719599A priority patent/EP1572916A4/en
Priority to JP2003584250A priority patent/JP2005534287A/en
Priority to MXPA04009728A priority patent/MXPA04009728A/en
Priority to CA002481503A priority patent/CA2481503A1/en
Priority to NZ535762A priority patent/NZ535762A/en
Publication of WO2003087306A2 publication Critical patent/WO2003087306A2/en
Priority to IL164390A priority patent/IL164390A/en
Publication of WO2003087306A8 publication Critical patent/WO2003087306A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
PCT/US2003/010462 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer WO2003087306A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0308953-3A BR0308953A (en) 2002-04-05 2003-04-04 compositions, protein, polynucleotide, method of generating an immune response, detection method, pharmaceutical composition, antibody or fragment thereof, transgenic animal, hybridoma, method of providing a cytotoxic agent or diagnostic agent and method of inhibiting cell growth cancerous
AU2003223469A AU2003223469A1 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
EP03719599A EP1572916A4 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
JP2003584250A JP2005534287A (en) 2002-04-05 2003-04-04 Nucleic acids named 98P4B6 and corresponding proteins useful in the treatment and detection of cancer
MXPA04009728A MXPA04009728A (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer.
CA002481503A CA2481503A1 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
NZ535762A NZ535762A (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98P4B6 (STEAP 2) useful in treatment and detection of cancer
IL164390A IL164390A (en) 2002-04-05 2004-10-04 Compositions comprising a peptide with a substituted amino acid at a primary anchor site

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37038702P 2002-04-05 2002-04-05
US60/370,387 2002-04-05
US10/165,044 US20030149531A1 (en) 2000-12-06 2002-06-06 Serpentine transmembrane antigens expressed in human cancers and uses thereof
US10/165,044 2002-06-06
US43548002P 2002-12-20 2002-12-20
US60/435,480 2002-12-20

Publications (2)

Publication Number Publication Date
WO2003087306A2 WO2003087306A2 (en) 2003-10-23
WO2003087306A8 true WO2003087306A8 (en) 2006-10-05

Family

ID=29255235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010462 WO2003087306A2 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Country Status (8)

Country Link
EP (1) EP1572916A4 (en)
JP (1) JP2005534287A (en)
AU (2) AU2003223469A1 (en)
BR (1) BR0308953A (en)
CA (1) CA2481503A1 (en)
MX (1) MXPA04009728A (en)
NZ (1) NZ535762A (en)
WO (1) WO2003087306A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
WO2006015165A2 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
AU2012322607B2 (en) 2011-10-14 2017-02-16 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
PT2906296T (en) 2012-10-12 2018-06-01 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ME03486B (en) 2012-10-12 2020-01-20 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2887899C (en) 2012-10-12 2020-03-31 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
EP2906298B1 (en) 2012-10-12 2018-10-03 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
LT2906253T (en) 2012-10-12 2018-10-10 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
CN105209077B (en) 2013-03-13 2019-06-11 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
AR096287A1 (en) 2013-03-13 2015-12-23 Spirogen Sàrl PIRROLOBENZODIACEPINS AND CONJUGATES
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
MX2016007578A (en) 2013-12-16 2016-10-03 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
BR112016012410A2 (en) 2013-12-16 2017-09-26 Genentech Inc drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition
MX2016007826A (en) 2013-12-16 2017-03-31 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CN107108724A (en) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 Cysteine engineered antibody and conjugate
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CA2968447A1 (en) 2014-11-25 2016-06-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (en) 2016-05-20 2021-09-29 Hoffmann La Roche PROTAC-Antibody Conjugates and Procedures for Use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
CA3037732A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20200032243A (en) 2017-02-08 2020-03-25 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (en) 2017-04-18 2022-08-29 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
DK3668874T3 (en) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RU2020113749A (en) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. ANALOGUES OF THAILANSTATIN
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (en) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP4132522A4 (en) * 2020-04-10 2024-05-22 Postsurgical Therapeutics Inc Combinatorial targeted therapy methods
EP4178625A1 (en) 2020-07-13 2023-05-17 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AR128331A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775366B2 (en) * 1999-12-06 2004-07-29 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2001249411B2 (en) * 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
AU2009230789A1 (en) 2009-11-19
AU2003223469A1 (en) 2003-10-27
NZ535762A (en) 2009-04-30
EP1572916A2 (en) 2005-09-14
CA2481503A1 (en) 2003-10-23
JP2005534287A (en) 2005-11-17
WO2003087306A2 (en) 2003-10-23
MXPA04009728A (en) 2005-06-08
BR0308953A (en) 2006-03-14
EP1572916A4 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
WO2003087306A8 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
AU2003243151A1 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
HK1152714A1 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1
EP1537140A4 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU2003232485A1 (en) Neopeptides and methods useful for detection and treatment of cancer
EP1517606A4 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
EP1622571A4 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
PT1537140E (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
AU2002257050A1 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
EP1590437A4 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2002083916A8 (en) Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
AU2002246708A1 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
EP1565200A4 (en) Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
WO2003085121A9 (en) Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
AU2003268355A1 (en) Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
AU2002254079A1 (en) Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
EP1545556A4 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
EP1499350A4 (en) Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
AU2003217112A1 (en) Method and kit for detection of mutations in mitochondrial dna
AU2002305170A1 (en) Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
ZA200501838B (en) Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/07980

Country of ref document: ZA

Ref document number: 200407980

Country of ref document: ZA

Ref document number: 2481503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009728

Country of ref document: MX

Ref document number: 2003584250

Country of ref document: JP

Ref document number: 535762

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003719599

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003223469

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038129876

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003719599

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0308953

Country of ref document: BR